Intelligent Bio Solutions Inc. completed precision testing for its Intelligent Fingerprinting Drug Screening System, a critical component for its upcoming FDA 510(k) submission to detect the opiate codeine. The testing involved over 1,600 tests conducted across three production runs and three independent sites, confirming consistent and reproducible performance. These results will be included in the regulatory application alongside existing data from cut-off, method comparison, and interference studies to support a planned U.S. market launch. The company is a medical technology firm developing non-invasive, rapid testing solutions via fingerprint sweat analysis.
